Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Cerebrovascular Aspects of Glycoprotein IIb/IIIa Inhibitors

  • Chapter
Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 56 Accesses

Abstract

The cerebrovascular complications of cardiac interventional trials are comprised of heterogeneous groups of ischemic and hemorrhagic brain injuries. These occur with varying frequencies determined by the characteristics of the patient population under study, the procedures involved and the combination and intensity of antitplatelet, antithrombotic, and fibrinolytic agents employed. Unraveling this complex interplay of factors contributing to all stroke subtypes is important not only to improve the overall outcome for patients with coronary disease, but also to develop successful treatments for patients with occlusive cerebrovascular disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Longstreth WT, Litwin PE, Weaver WD. Myocardial infarction, thrombolytic therapy, and stroke. The MITI Project Group. Stroke 1993; 24: 587–590.

    Article  PubMed  Google Scholar 

  2. Sloan MA, Price TR, Terrin ML, Forman S, Gore JM, Chaiatman BR, Hodges M, Mueller H, Rogers WJ, Knotterud GL, Braunwald E. Ischemic cerebral infarction after rt-PA and heparin therapy for acute myocardial infarction. The TIMI-II pilot and randomized clinical trial combined experience. Stroke 1997; 28: 1107–1114.

    Article  PubMed  CAS  Google Scholar 

  3. Mahaffey KW, Granger CB, Sloan MA, Thompson TD, Gore JM, Weaver WD, White HD, Simoons ML, Barbash GI, Topol EJ, Califf RM. Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I. Circulation 1998; 97: 757–764.

    Article  PubMed  CAS  Google Scholar 

  4. Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, Barbash GI, Van de Werf F, Aylwaard PE, Topol EJ, Califf, RM. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Circulation 1995; 92: 2811–2818.

    Article  PubMed  CAS  Google Scholar 

  5. Sila CA. Neurologic complications of vascular surgery. Neurol Clin No Am 1998; 16: 9–20.

    Article  CAS  Google Scholar 

  6. Dawson DM, Fischer EG. Neurologic complications of cardiac catheterization. Neurology 1977; 27: 496–497.

    Article  PubMed  CAS  Google Scholar 

  7. Galbreath C, Salgado ED, Furlan AJ, Hollman J. Central nervous system complications of percutaneous transluminal coronary angioplasty. Stroke 1986; 17: 616–619.

    Article  PubMed  CAS  Google Scholar 

  8. Kosmorsky G, Hanson MR, Tomsak RL Neuro-ophthalmologic complications of cardiac catheterization. Neurology 1986; 38: 483–485.

    Article  Google Scholar 

  9. The CAPTURE Investigators. Refractory unstable angina reduction of events by treatment with abciximab prior to coronary intervention. Lancet 1997; 349: 1429–1435.

    Article  Google Scholar 

  10. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956–961.

    Article  Google Scholar 

  11. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 24: 1689–1696.

    Google Scholar 

  12. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II Lancet 1997; 349: 1422–1428.

    Article  Google Scholar 

  13. Babikian VL, Kase CS, Pessin MS, Norrving B, Gorelick PB. Intracerebral hemorrhage in stroke patients anticoagulated with heparin. Stroke 1989; 20: 1500–1503.

    Article  PubMed  CAS  Google Scholar 

  14. Cerebral Embolism Study Group. Cardiogenic stroke, early anticoagulation, and brain hemorrhage. Arch Intern Med 1987; 147: 636–639.

    Article  Google Scholar 

  15. Shields RW Jr, Laureno R, Lachman T, Victor M. Anticoagulant-related hemorrhage in acute cerebral embolism. Stroke 1984; 15: 426–437.

    Article  PubMed  Google Scholar 

  16. Gebel J, Sila CA, Sloan MA, Granger CB, Mahaffey KW, Weisenberger J, Green CL, White HD, Gore IM, Weaver WD, Califf RM, Topol EJ. Thrombolysis-related intracranial hemorrhage. A radiographic analysis of 244 cases from the GUSTO-I trial with clinical correlation. Stroke 1998; 29: 563–569.

    Article  PubMed  CAS  Google Scholar 

  17. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–682.

    Article  Google Scholar 

  18. Sloan MA, Sila CA, Mahaffey KW, Granger CB, Long streth WT Jr, Koudstaal P, White HD, Gore JM, Simoons ML, Weaver WD, Green CL, Topol EJ, Califf RM. Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. Circulation 1998; 98: 1376–1382.

    Article  PubMed  CAS  Google Scholar 

  19. Widjicks EFM, Jack C. Intracerebral hemorrhage after fibrinolytic therapy for acute myocardial infarction. Stroke 1993; 24: 554–557.

    Article  Google Scholar 

  20. Vaitkus PT, Berlin JA, Schwartz JS, Barnathan ES. Stroke complicating acute myocardial infarction-a meta-analysis of risk modification by anticoagulation and thrombolytic therapy. Arch Intern Med 1992; 152: 2020–2024.

    Article  PubMed  CAS  Google Scholar 

  21. Vorchheimer DA, Fuster V. Oral glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety. Circulation 1998; 97: 312–314.

    Article  PubMed  CAS  Google Scholar 

  22. PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498–1505.

    Article  Google Scholar 

  23. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 1998; 338: 1488–1497.

    Article  Google Scholar 

  24. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445–1453.

    Article  Google Scholar 

  25. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3Fab following thrombolytic therapy: results of the TAMI 8 pilot study. J Am Coll Cardiol 1993; 22: 381–389.

    Article  PubMed  CAS  Google Scholar 

  26. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley D, Anderson HV, Ellis SG, Cohen MD, Spriggs D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KN, Califf RM, Mitchell MW, Topol EJ. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Circulation 1997; 95: 846–854.

    Article  PubMed  CAS  Google Scholar 

  27. Rundek T, Elkind MS, Chen X, Boden-Albala B, Paik C, Sacco RL. Increased early stroke recurrence among patients with extracranial and intracranial atherosclerosis: The Northern Manhattan Stroke Study. Neurology 1998; 50: A75.

    Google Scholar 

  28. Sacco RL, Foulkes MA, Mohr JP, Wolf PA, Hier DB, Price TR. Determinants of early recurrence of cerebral infarction, The Stroke Data Bank. Stroke 1989; 20: 983–989.

    Article  PubMed  CAS  Google Scholar 

  29. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991; 325: 445–453.

    Article  Google Scholar 

  30. FDA Drug Bulletin Editorial Board. Aspirin for transient ischemic attacks. FDA Drug Bull 1980; 10: 2.

    Google Scholar 

  31. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320–331.

    Article  Google Scholar 

  32. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. Br Med J 1988; 296: 316–320.

    Article  Google Scholar 

  33. The SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 1991; 338: 1345–1349.

    Article  Google Scholar 

  34. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261–1266.

    Article  Google Scholar 

  35. Bousser MG, Eschwege E, Haguenau M, LeFucconnier JM, Thibult N, Touboul PJ. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983; 14: 5–14.

    Article  PubMed  CAS  Google Scholar 

  36. ESPS Group. European stroke prevention study. Stroke 1990; 21: 1122–1130.

    Article  Google Scholar 

  37. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European stroke prevention study 2. Dipuridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13.

    Article  PubMed  Google Scholar 

  38. Gent M, Blakely JA, Easton JD, et al and the CATS Group. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215–1220.

    Article  PubMed  CAS  Google Scholar 

  39. Hass WK, Easton JD, Adams HP, et al for the Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. N Engl J Med 1989; 321: 501–507

    Article  PubMed  CAS  Google Scholar 

  40. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998; 128: 541–544.

    PubMed  CAS  Google Scholar 

  41. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329–1339.

    Article  Google Scholar 

  42. Yadav JS, Roubin GS, Iyer SS, Vitek J, King P, Jordan WD, Fisher WS. Elective stenting of the extracranial carotid arteries. Circulation 1997; 95: 376–381.

    Article  PubMed  CAS  Google Scholar 

  43. Wallace RC, Furlan AJ, Moliterno DJ, Stevens GHJ, Masaryk TJ, Perl J. Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIb/IIIa receptor inhibitor. Am J Neuroradiol 1997; 18: 1257–1260.

    PubMed  CAS  Google Scholar 

  44. Mohammad YM, Samuels OB, Stern BJ, Joseph GJ, Miller DA, Dawson RC, Howlett-Smith HA, Chimowitz MI. Percutaneous transluminal angioplasty (PTA) plus abciximab for symptomatic vertebrobasilar stenosis. Neurology 1998; 50: A156.

    Google Scholar 

  45. Chinese Acute Stroke Trial Collaborative Group. Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet 1997; 349: 1641–1649.

    Article  Google Scholar 

  46. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet 1997; 349: 1569–1581.

    Article  Google Scholar 

  47. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–1587.

    Article  Google Scholar 

  48. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, MeNeil JJ, Rosen D, Stewart-Wynne EG, Tuck RR. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996; 276: 961–966.

    Article  PubMed  CAS  Google Scholar 

  49. The Multicentre Acute Stroke Trial-Europe Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996; 335: 145–150.

    Article  Google Scholar 

  50. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Lancet 1995; 346: 1509–1514.

    Google Scholar 

  51. Rebello SS, Driscoll EM, Lucchesi BR. TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog. Stroke 1997; 28: 1789–1796.

    Article  PubMed  CAS  Google Scholar 

  52. delZoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O, Greenlee R, Brass L, Mohn JP, Feldmann E, Hacke W, Kase CS, Biller J, Gress D, Otis SM. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32: 78–86.

    Article  CAS  Google Scholar 

  53. Madden KP, Karanjia PN, Adams HP, Clarke WR. Accuracy of initial stroke subtype diagnosis in the TOAST study. Trial of ORG 10172 in acute stroke treatment. Neurology 1995; 45: 1975–1979.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Cathy A. Sila MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Experimental Interventional Laboratory, Joseph J. Jacobs Center for Thrombosis and Vascular Biology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

    A. Michael Lincoff MD (Associate Professor of Medicine. Director) (Associate Professor of Medicine. Director)

  2. Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

    A. Michael Lincoff MD (Associate Professor of Medicine. Director) & Eric J. Topol MD (Professor of Medicine, Chairman. Director) (Associate Professor of Medicine. Director) &  (Professor of Medicine, Chairman. Director)

  3. Joseph J. Jacobs Center for Thrombosis and Vascular Biology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

    Eric J. Topol MD (Professor of Medicine, Chairman. Director) (Professor of Medicine, Chairman. Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Sila, C.A. (1999). Cerebrovascular Aspects of Glycoprotein IIb/IIIa Inhibitors. In: Lincoff, A.M., Topol, E.J. (eds) Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-724-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-724-6_15

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6202-0

  • Online ISBN: 978-1-59259-724-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation